It could be speculated that in tumor cells a part of the regulatory process by HBx has likely been lost, or SELENBP1 might preferentially be regulated by other inhibitory mechanisms common in many cancers, such as epigenetic changes. This evidence concerns the gene SELENBP1 and cancer.